医学分子生物学杂志 ›› 2022, Vol. 19 ›› Issue (1): 33-40.doi: 10.3870/j.issn.1672-8009.2022.01.005

• 论著 • 上一篇    下一篇

利多卡因下调 ABCG2 抑制人乳腺癌细胞的活性和耐药性 

  

  1. 西安交通大学第一附属医院麻醉手术部 西安市, 710061
  • 出版日期:2022-01-31 发布日期:2022-02-25
  • 基金资助:
    陕西省自然科学基金 (No. 2019JQ-354)

Lidocaine Inhibits the Activity and Drug Resistance of Human Breast Cancer Cells by Down-regulating ABCG2

  • Online:2022-01-31 Published:2022-02-25

摘要: 目的 探究利多卡因体外下调 ATP 结合转运蛋白 G 家族成员 2 (ATP binding cassette transporter G family member 2, ABCG2) 抑制人乳腺癌细胞的活性及顺铂耐药性的可能机制。 方法 选取 MDA-MB-231、 MCF-7 细胞, 使用 CCK-8、 EdU、 TUNEL 法染色验证利多卡因对细胞增殖活性、 顺铂干预增敏作用, RT-PCR 和 Western 印迹法检测利多卡因对 ABCG2 以及凋亡蛋白、 耐药蛋白表达及 PI3K/ Akt 蛋白磷酸化的影 响; CCK-8 法、 TUNEL 法验证过表达 ABCG2 对利多卡因联合顺铂干预乳腺癌细胞系增殖活性、 凋亡率。 结果 0. 5 mmol / L 干预时乳细胞存活率及 EdU 阳性细胞数显著降低 (P< 0. 05); 与对照组相比, 利多卡因 组和顺铂组细胞存活率、 Bcl-2 表达显著降低, 细胞凋亡率、 Cleaved-PARP、 Cleaved-caspase-3、 Bax 表达量 显著升高, 联合处理后变化更显著 (P< 0. 05); 利多卡因处理后, 癌细胞系中 ABCG2 mRNA 及蛋白表达水 平降低 (P< 0. 05); 与对照组比较, 顺铂 + 利多卡因组 ABCG2、 P-gp、 MRP1、 MRP2 蛋白表达显著降低 (P <0. 05); 与顺铂组比较, 利多卡因组细胞存活率、 p-PI3K/ PI3K、 p-AKT/ AKT 表达显著降低 (P< 0. 05), 细胞凋亡率显著升高 (P< 0. 05); 与空质粒组比较, ABCG2 过表达组细胞存活率、 p-PI3K/ PI3K、 p-AKT/ AKT 表达显著升高 (P< 0. 05), 细胞凋亡率显著降低 (P< 0. 05)。 结论 利多卡因可能通过抑制 ABCG2 表达及 PI3K/ AKT 信号通路的激活抑制乳腺癌细胞增殖活性及提高对顺铂敏感性。

关键词: 乳腺癌, 利多卡因, ATP 结合转运蛋白 G 家族成员 2, 顺铂, 耐药性 

Abstract: Objective To explore the possible mechanisms by which lidocaine inhibits the activity and cisplatin resistance of human breast cancer cells by down-regulating ATP binding cassette transporter G family member 2 (ABCG2) in vitro. Methods The effects of lidocaine on cell proliferation and cisplatin intervention were verified in MDA-MB-231 and MCF-7 cells by CCK-8, EdU and TUNEL staining. The effects of lidocaine on the expressions of ABCG2, apoptosis proteins and drug resistance proteins were detected by RT-PCR and Western blotting; the phosphorylation of PI3K/ Akt proteins was detected by Western blotting. The effects of ABCG2 overexpression on the proliferation and apoptosis of breast cancer cells after intervention with lidocaine and cisplatin were verified by CCK-8 and TUNEL. Results After intervention with 0. 5 mmol / L lidocaine, the survival rate of breast cancer cells and the number of EdU-positive cells were significantly decreased (P< 0. 05). The survival rate of cells and the Bcl-2 expression were significantly decreased, the apoptosis rate and the expression levels of cleaved-PARP, cleaved-caspase-3 and Bax were significantly increased in lidocaine group and cisplatin group when compared with the control group. These changes were more obvious in cisplatin + lidocaine group (P < 0. 05). After lidocaine treatment, the expression levels of ABCG2 mRNA and protein in cancer cells were decreased (P< 0. 05). The expression levels of ABCG2, P-gp, MRP1 and MRP2 proteins were significantly decreased in cisplatin + lidocaine group when compared with the control group (P< 0. 05). The survival rate of cells and the levels of p-PI3K/ PI3K and p-AKT / AKT were significantly decreased (P < 0. 05), while the apoptosis rate was significantly increased in lidocaine group as compared to cisplatin group (P< 0. 05). The survival rate of cells and the levels of p-PI3K/ PI3K and p-AKT / AKT were significantly increased (P < 0. 05 ), while the apoptosis rate was significantly decreased in ABCG2 overexpressed group compared to the empty plasmid group (P< 0. 05). Conclusion Lidocaine could inhibit the proliferation of breast cancer cells and increase their sensitivity to cisplatin by inhibiting ABCG2 expression and activation of PI3K/ AKT signaling pathways.

Key words: breast cancer, lidocaine, ATP binding cassette transporter G family member 2, cisplatin, drug resistance 

中图分类号: